Malignant Peripheral Nerve Sheath Tumor Overview

Save information for later
Sign Up

Learn About Malignant Peripheral Nerve Sheath Tumor

What is the definition of Malignant Peripheral Nerve Sheath Tumor?
A Malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1.
What are the alternative names for Malignant Peripheral Nerve Sheath Tumor?
  • Malignant peripheral nerve sheath tumor
  • MPNST
  • Malignant neurilemmoma
  • Malignant neurofibroma
  • Malignant schwannoma
  • Neurofibrosarcoma
  • Neurogenic sarcoma
Who are the top Malignant Peripheral Nerve Sheath Tumor Local Doctors?
Elite in Malignant Peripheral Nerve Sheath Tumor
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology
Elite in Malignant Peripheral Nerve Sheath Tumor
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Tap is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization.

Elite in Malignant Peripheral Nerve Sheath Tumor
Dr. Angela Hirbe
Oncology
Elite in Malignant Peripheral Nerve Sheath Tumor
Dr. Angela Hirbe
Oncology

Washington University

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
314-747-3000
Languages Spoken:
English
See accepted insurances

Angela Hirbe is an Oncologist in Saint Louis, Missouri. Dr. Hirbe is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Neurofibromatosis Type 1 (NF1), and Adult Soft Tissue Sarcoma.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Malignant Peripheral Nerve Sheath Tumor
Dr. Brian Van Tine
Oncology
Elite in Malignant Peripheral Nerve Sheath Tumor
Dr. Brian Van Tine
Oncology

Washington University

5201 Mid America Plz, 
Saint Louis, MO 
Languages Spoken:
English
See accepted insurances

Brian Van Tine is an Oncologist in Saint Louis, Missouri. Dr. Van Tine is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, and Malignant Peripheral Nerve Sheath Tumor.

View All Doctors
What are the latest Malignant Peripheral Nerve Sheath Tumor Clinical Trials?
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Who is this study for: Patients with metastatic solid tumors
Enrollment Status: Recruiting
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drug: Metarrestin
Study Phase: Phase 1

Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant organs.

Match to trials
Find the right clinical trials for you in under a minute
Get started
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Who is this study for: Patients with Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drugs: Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells
Study Phase: Phase 1

Summary: 3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center